Inanovate Inc. Welcomes New CEO Kamran Tahamtanzadeh
healthcaretechoutlook

Inanovate Inc. Welcomes New CEO Kamran Tahamtanzadeh

Healthcare Tech Outlook | Monday, January 24, 2022

Inanovate has hired a new CEO to help guide the company into its next growth phase and bring novel new cancer blood testing technology to the clinic.

FREMONT, CA: "Inanovate is a truly innovation-driven company as its name references and is looking to address critical needs in the life sciences field and within molecular diagnostics and Bio-Pharma fields with a sharp focus on breast cancer diagnosis and monitoring. The two initial problems we seek to address are: the over-diagnosis of breast cancer by mammograms and the lack of accurate tests for monitoring cancer recurrence. Our tests combine the Bio-ID platform with multiple patent-protected breast cancer-specific biomarkers," states Kamran Tahamtanzadeh, CEO, Inanovate. CEO Kamran Tahamtanzadeh has been named to lead Inanovate. The flagship instrument platform of Inanovate, a leading molecular diagnostics company, measures the time-course rates of protein-protein interactions using a breakthrough blood-based proteomics platform (the Bio-ID). The Bio-unique ID's ability to accurately detect and measure dozens of different proteins in a single, automated, low-cost test is being leveraged in developing a blood test for the diagnosis of breast cancer.

"We are delighted to welcome Kamran to the Inanovate team as our new CEO. With his highly practical and relevant, results-driven experience within the molecular diagnostics field, coupled to his clinical diagnostics, regulatory, and commercialization network, we are confident that Kamran will lead the company in its next phase of growth to becoming a leader in protein-based detection and measurement, with an initial application focus on reliable, low-cost blood tests for cancer," states David Ure, Chairman & Founder, Inanovate.

Mr. Tahamtanzadeh has nearly three decades of scientific, technology-product commercialization, mergers and acquisitions, and investor relations experience in the pharma-cancer diagnostics and digital health industries.

As a former C-level executive in the life sciences, cancer biopharmaceutical, and diagnostics industries with notable roles at Exosomics S.p.A. (acquired by Lonza Therapeutics), the founder and CEO of PrognosDx Health Inc., and Director of the Translational Diagnostics Business, he joins Inanovate. He previously worked as a management consultant and as a C-level executive.

Before joining Beckman Coulter, Kamran was an R&D chemist for seven years, a ProteomeLab specialist at Beckman Coulter, and a corporate advisory board member at Crystal Genetics Inc. Kamran has a proven track record of success in the fields of companion diagnostics and cancer epigenetics, which he has demonstrated in his various executive positions. SABs, Boards of Directors, and commercial teams with lean organizations achieving rapid commercial growth have all been built by him over the past two decades. Many technology developments and due diligence projects have been completed by Kamran and private placements with angel investors and strategic corporate venture funds.

Weekly Brief